Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0325814116
Thu, 27.04.2023
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales accelerate from 2.6 million to CHF 5.6 million
Key data on efficacy of MagnetOs bone graft published in two prestigious, peer-reviewed scientific journals
Kuros [ … ]
Wed, 15.03.2023
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Financial highlights
Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total revenue from medical devices CHF 13.3 million, up from CHF 8.3 million
Revenue from collaboration CHF 4.7 million vs CHF 5.5 million in 2021, due to licensing agreement [ … ]
Wed, 15.03.2023
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Financial highlights
Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total revenue from medical devices CHF 13.3 million, up from CHF 8.3 million
Revenue from collaboration CHF 4.7 million vs CHF 5.5 million in 2021, due to licensing agreement [ … ]
Thu, 16.02.2023
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
New Chief Financial Officer (CFO) ad interim
Schlieren (Zurich), Switzerland, 16 February 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad [ … ]
Thu, 16.02.2023
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
New Chief Financial Officer (CFO) ad interim
Schlieren (Zurich), Switzerland, 16 February 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad [ … ]
Wed, 26.10.2022
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Total product sales grow to CHF 8.9 million in the first nine months of 2022
Reaches major milestone of 10,000 patients treated with MagnetOs
Positive first clinical data from planned randomized controlled trials
Full commercial launch of MagnetOs Flex Matrix that recently recei [ … ]
Wed, 26.10.2022
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Total product sales grow to CHF 8.9 million in the first nine months of 2022
Reaches major milestone of 10,000 patients treated with MagnetOs
Positive first clinical data from planned randomized controlled trials
Full commercial launch of MagnetOs Flex Matrix that recently recei [ … ]
Mon, 03.10.2022
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Schlieren (Zurich), Switzerland, October 3, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal an [ … ]
Mon, 03.10.2022
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Schlieren (Zurich), Switzerland, October 3, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal an [ … ]
Thu, 15.09.2022
Kuros Biosciences AG
Schlieren (Zurich), Switzerland, September 15, 2022 – Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the "New Shares" and the "Placement [ … ]